Neutralisation of interferon gamma - A new trend in therapy of rheumatoid arthritis

Terapevticheskii Arkhiv

Volumn 80, Issue 5, 2008, Pages 30-37

  Nasonova, V A ^a   Lukina, G V ^a   Sigidin, Ya A ^a  

^a NONE

Author keywords

Antibodies to interferon gamma; Antibodies to tumor necrosis factor alpha; Anticytokines; Rheumatoid arthritis

Indexed keywords

ANTIBODY; C REACTIVE PROTEIN; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; FEMALE; FOLLOW UP; HUMAN; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ANTIBODIES; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERFERON TYPE II; MALE; MIDDLE AGED; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 46049100570     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Skurkovich S. V., Klimova K. G., Eremkina E. I. et al. Immunosuppressive effect of an anti-interferon serum. Nature 1974; 247: 551-552.
2. Feldmann M., Brennan F. M., Maini R. N. Role of cytokines in rheumatoid arthritis. Ann. Rev. Immunol. 1996; 14: 397-440.
3. Lipsky P., Heijde van der D., St Clair E. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med. 2000; 343: 1594-1602.
4. Moreland L. W., Schiff M. H., Baumgartner S. W. et al. Etanercept therapy in rheumatoid arthritis. Ann. Intern. Med. 1999; 130: 478-486.
5. Weinblatt M. E., Keystone E. C., Furst D. E. et al. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann. Rheum. Dis. 2006; 65 (6): 753-759.
6. Michaud K., Wolfe F. Reduced mortality among RA patients treated with anti-TNF therapy and methotrexate. Ann. Rheum. Dis. 2005; 64 (suppl. III): 87.
7. Genant H. K. Interleukin-1 receptor antagonist treatment of rheumatoid arthritis patients. Semin. Arthr. Rheum. 2001; 30 (suppl. 2): 26-32.
8. Kremer J., Westhovens R., Moreland L. et al. Efficacy and safety of the selective co-stimulation modulator abatacept with methotrexate in treating rheumatoid arthritis. Arthr. and Rheum. 2004; 50 (12): 4095.
9. Cohen S. B., Emery P., Greenwald M. W. et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthr. and Rheum. 2006; 54 (9): 2793-2806.
10. Billiau A. Interferon-γ in autoimmunity. Cytokine Growth Factor Rev. 1996; 7(1): 25-34.
11. Lotz M. Cytokines and their receptors. In: Koopman W. J., ed. Arthritis and allied conditions. 13-th ed. Baltimore: Williams & Wilkins; 1996. 439-478.
12. Nakamura M., Manser T., Pearson G. et al. Effect of IFN-gamma on the immune response in vivo and in gene expression in vitro. Nature 1984; 307: 381-382.
13. Dancis V., Frank G., Rathgen D. et al. Effect of GM-CSF, IL-2, IFN-gamma, TNF-alfa and IL-6 on the production of immunoreactive IL-1 and TNF-alfa by human monocytes. Clin. Exp. Immunol. 1991; 85: 143-147.
14. Dayer J. M. Cytokines, soluble cytokine receptors and cytokine receptor antagonists. EULAR Bull. 1992; 21: 7-14.
15. Duff G. W. Cytokines and acute phase proteins in rheumatoid arthritis. Scand. J. Rheumatol. 1994; 23 (suppl. 100): 9-19.
16. Pike M. C. Structure and function of monocytes and macrophages. In: Koopman W. J., ed. Arthritis and allied conditions. 13-th ed. Baltimore: Williams & Wilkins; 1996. 339-354.
17. Prud'homme G. J., Lawson B. R., Theophylopoulos A. N. Anti-cytokine gene therapy of autoimmune diseases. Expert Opin. Biol. Ther. 2001; 1: 359-373.
18. Machold K. P., Smolen J. S. Interferon-gamma induced exacerbation of systemic lupus erythematosus. J. Rheumatol. 1990; 17: 831-832.
19. Dolhain R. J., ter Haar N. T., Hoefakker S. et al. Increased expression of interferon (IFN)-gamma together with IFN-gamma receptor in the rheumatoid synovial membrane compared with synovium of patients with osteoarthritis. Br. J. Rheumatol. 1996; 35 (1): 24-32.
20. Steiner G. IL-1, IL-6, TNF-alfa and IFN-gamma: serum and synovial fluid concentration in rheumatoid arthritis. EULAR Cong. Rep. 1992; 1: 19-20.
21. Russian source
22. Russian source
23. Arnett F. C., Edworthy S. M., Bloch D. A. et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthr. and Rheum. 1988; 31 (3): 315-324.
24. Skurkovich S. V., Loukina G. V., Sigidin Y. A. et al. Successful first-time use of antibodies to interferon-gamma alone and combined with antibodies to tumor necrosis factor-alfa to treat rheumatic diseases (rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, Behcet's syndrome). Inter. J. Immunother. 1998; 14 (1): 23-32.
25. Felson D. T., Anderson J. J., Boers M. et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthr. and Rheum. 1993; 36 (6): 729-740.
26. Elliot M. J., Maini R. N., Feldmann M. et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumour necrosis factor a. Arthr. and Rheum. 1993; 36 (12): 1681-1690.
27. Maini R., Breedveld F., Kalden J. et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthr. and Rheum. 1998; 41 (9): 1552-1563.
28. Sigidin Y. A., Loukina G. V., Skurkovich B. et al. Randomized, double-bund trial of anti-interferon-γ antibodies in rheumatoid arthritis. Scand. J. Rheumatol. 2001; 30 (4): 203-207.
29. Skurkovich S. V., Boiko A, Beliaeva I. et al. Randomized study of antibodies to IFN-γ and TNF-α in secondary progressive multiple sclerosis. Multiple Scleros. 2001; 7: 277-284.
30. Panitch H. S., Folus J. S., Johnson K. P. Recombinant β-interferon inhibits γ-interferon production in multiple sclerosis. Ann. Neurol. 1987; 22: 139.
31. Skurkovich S., Kasparov A., Narbut N. et al. Treatment of corneal transplant rejection in humans with anti-interferon-γ antibodies. Am. J. Ophthalmol. 2002; 133: 136-137.
32. th Asia pacific congress of allergology and clinical immunology. Bologna: Monduzzi; 2002. 121-125.
33. Ettefagh L., Nedorost S., Mirmirani P. Alopecia areata in a patient using infliximab. Arch. Dermatol. 2004; 140: 1012.
34. Hommes D. W., Mikhajlova T. L., Stoinov S. et al. Fontolizumab, a humanised anti-interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 2006; 56: 1131-1137.
35. Crow M. K. Interferon-α: A new target for therapy in systemic lupus erythematosus? Arthr. and Rheum. 2003; 48 (9): 2396-2401.